Back to Search Start Over

Prevention of joint destruction in patients with high disease activity or high C-reactive protein levels: Post hoc analysis of the GO-FORTH study

Authors :
Naoki Ishiguro
Yutaka Ishii
Takao Koike
Tsutomu Takeuchi
Daniel Baker
Masayoshi Harigai
Hisashi Yamanaka
Kazuhiko Yamamoto
Nobuyuki Miyasaka
Hiroshi Nakajima
Yoshiya Tanaka
Source :
Modern Rheumatology. 26:323-330
Publication Year :
2015
Publisher :
Oxford University Press (OUP), 2015.

Abstract

To assess the influence of golimumab dosage and disease activity on joint destruction in patients with active rheumatoid arthritis (RA) in the GO-FORTH study.Efficacy was compared among groups given basal methotrexate plus placebo, golimumab (50 mg), or golimumab (100 mg) with stratification by high (HDA) or moderate (MDA) baseline disease activity and by high or low baseline C-reactive protein (CRP).Among HDA or high CRP patients, the mean change of the total Sharp score was 3.48 and 3.41 in the placebo group, 1.94 and 2.71 in the 50 mg group, and 0.39 and 1.15 in the 100 mg group, respectively. The percentage of progression-free patients with HDA or high CRP was 40.4% and 40.0%, 43.1% and 38.2%, and 69.8% and 61.5%, respectively. Among MDA or low CRP patients, both golimumab doses showed similar prevention of joint destruction. Among HDA or high CRP patients, a shorter disease duration and higher TSS/disease duration ratio were associated with joint destruction.Both doses of golimumab (50 or 100 mg) prevented joint destruction in MDA or low CRP patients, but 100 mg was better for HDA or high CRP patients with a shorter disease duration or higher TSS/disease duration ratio.

Details

ISSN :
14397609 and 14397595
Volume :
26
Database :
OpenAIRE
Journal :
Modern Rheumatology
Accession number :
edsair.doi.dedup.....e7bfb550bb0128f39ccc1b0003316889
Full Text :
https://doi.org/10.3109/14397595.2015.1086041